| Business Summary | | Qiagen
N.V.
provides
enabling
technologies
and
products
for
the
separation
and
purification
of
nucleic
acids.
Qiagen
has
developed
and
marketed
products
for
the
academic
and
industrial
research
market.
The
Company
is
a
holding
company
for
its
wholly
owned
subsidiaries
QIAGEN
GmbH
(Germany),
QIAGEN
Inc.
(United
States),
QIAGEN
Ltd.
(England),
QIAGEN
AG
(Switzerland),
QIAGEN
SA
(France),
QIAGEN
Pty.
Ltd.
(Australia),
QIAGEN
Inc.
(Canada),
QIAGEN
Instruments
AG,
formerly
Rosys
Instruments
AG,
(Switzerland)
and
QIAGEN
Genomics
Inc.,
formerly
Rapigene
Inc.
(United
States).
The
Company
also
has
a
60%
interest
in
QIAGEN
K.K.
in
Tokyo,
Japan
and
a
50%
interest
in
Rosys
Inc.
in
the
United
States.
The
Company
has
established
two
new
subsidiaries
located
in
the
United
States,
QIAGEN
North
American
Holdings
Inc.,
established
as
a
holding
company
for
the
United
States
subsidiaries,
and
QIAGEN
Sciences
Inc.,
the
Company's
new
North
American
manufacturing
and
research
and
development
headquarters. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | QGENF
produces
and
distributes
biotechnology
products
for
the
separation
and
purification
of
nucleic
acids
(DNA/RNA).
The
Company
also
assembles
and
distributes
robotic
equipment
to
be
used
with
its
products.
For
the
six
months
ended
6/01,
revenues
increased
25%
to
$129.2
million.
Net
income
totaled
$17.3
million,
up
from
$7.5
million.
Revenues
reflect
higher
unit
sales
of
consumable
and
QIAGEN
instrumentation
products.
Net
income
reflects
a
gain
on
foreign
currency. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Carsten Claussen, Ph.D., 71 | Chairman
of the Supervisory Board | Metin Calpan, Ph.D., 44 | CEO
and Managing Director | Peer Schatz, 33 | CFO
and Managing Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|